Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01929642CT.gov Rapalogues for Autism Phenotype in TSC: A Feasibility Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Autism
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Everolimus (this asset) | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | P2 | B · 57 |
| Lurasidone | Sumitomo Pharma America, Inc. | P3 | BB |
| Sirolimus | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | P2 | B |
| Sertraline | Holland Bloorview Kids Rehabilitation Hospital | P2 | CCC |
| Cholesterol Suspension | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | P1/2 | CCC |
| Brexpiprazole | Otsuka Pharmaceutical Development & Commercialization, Inc. | P1 | CC |
| Fluoxetine | Icahn School of Medicine at Mount Sinai | N/A | D |
Other indications for Everolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuberous Sclerosis | — | P3 | BBB · 76 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 75 |
| Hodgkins Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- LurasidoneSumitomo Pharma America, Inc.BB
- SirolimusHugo W. Moser Research Institute at Kennedy Krieger, Inc.B
- SertralineHolland Bloorview Kids Rehabilitation HospitalCCC
- Cholesterol SuspensionEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)CCC
- BrexpiprazoleOtsuka Pharmaceutical Development & Commercialization, Inc.CC
Citation
Floatz Terminal. Everolimus in Autism. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/everolimus-autism
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →